Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats

Ibragić, Saida; Matak, Ivica; Dračić, Aida; Smajlović, Ahmed; Muminović, Mehmed; Proft, Florijan; Sofić, E.; Lacković, Zdravko; Riederer, Peter

doi:10.1016/j.neulet.2016.02.020

Cited by 21 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the orofacial formalin test, BoNT/A injected into the whisker pad did not modulate the levels of monoamines and their metabolites, not supporting their in the BoNT/A antinociceptive action [119]. BoNT/A’s effect on ascending pain processing in humans has not been examined by functional imaging studies.…”

Section: Actions Of Bont/a In the Central Nervous Systemmentioning

confidence: 99%

Mechanisms of Botulinum Toxin Type A Action on Pain

Matak

Bölcskei

Bach-Rojecky

et al. 2019

Toxins

175

127

View full text Add to dashboard Cite

Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic and other chronic pain disorders. In comparison with other conventional and non-conventional analgesic drugs, the greatest advantages of BoNT/A use are its sustained effect after a single application and its safety. Its efficacy in certain therapy-resistant pain conditions is of special importance. Novel results in recent years has led to a better understanding of its actions, although further experimental and clinical research is warranted. Here, we summarize the effects contributing to these advantageous properties of BoNT/A in pain therapy, specific actions along the nociceptive pathway, consequences of its central activities, the molecular mechanisms of actions in neurons, and general pharmacokinetic parameters.

show abstract

Section: Actions Of Bont/a In the Central Nervous Systemmentioning

confidence: 99%

Mechanisms of Botulinum Toxin Type A Action on Pain

Matak

Bölcskei

Bach-Rojecky

et al. 2019

Toxins

175

127

View full text Add to dashboard Cite

show abstract

“…Recently, in addition to the known improvement of motor performance, an antidepressantlike effect has been demonstrated following intrastriatal injection of BoNT/A (1 ng; two injections of 1 µL solution) in a hemi-PD rat model [110]. Regarding the effects of BoNTs in depression, Ibragic et al [111] quantified the concentrations of dopamine (DA), noradrenaline (NA), serotonin (5-HT), and their metabolites in brain regions, ipsilateral, and contralateral, from the site of unilateral BoNT/A administration (5 U/Kg of Botox ® ) into the rat whisker pad. From this analysis, authors found a significant increase of NA in striatum and 5-HT in hypothalamus demonstrating an efficacy role for BoNT/A in the treatment of depression.…”

Section: Central Effects Of Bonts After Direct Injection On Cnsmentioning

confidence: 99%

Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy

Luvisetto

2021

Toxins

View full text Add to dashboard Cite

Botulinum neurotoxins (BoNTs) are potent inhibitors of synaptic vesicle fusion and transmitter release. The natural target of BoNTs is the peripheral neuromuscular junction (NMJ) where, by blocking the release of acetylcholine (ACh), they functionally denervate muscles and alter muscle tone. This leads them to be an excellent drug for the therapy of muscle hyperactivity disorders, such as dystonia, spasticity, and many other movement disorders. BoNTs are also effective in inhibiting both the release of ACh at sites other than NMJ and the release of neurotransmitters other than ACh. Furthermore, much evidence shows that BoNTs can act not only on the peripheral nervous system (PNS), but also on the central nervous system (CNS). Under this view, central changes may result either from sensory input from the PNS, from retrograde transport of BoNTs, or from direct injection of BoNTs into the CNS. The aim of this review is to give an update on available data, both from animal models or human studies, which suggest or confirm central alterations induced by peripheral or central BoNTs treatment. The data will be discussed with particular attention to the possible therapeutic applications to pathological conditions and degenerative diseases of the CNS.

show abstract

“…Increasingly, BoNT-A has been used in the treatment of chronic pain conditions like diabetic neuropathy, trigeminal neuralgia, arthritis, low back pain, myofascial pain, and has been approved for chronic migraine headache treatment in 2010. One of the most surprising new reports of toxin beneficial effect is the treatment of major depressive disorder (Ibragić S. et al, 2016) even confirmed by controlled clinical trials. In cosmetic medicine, the most widely known use of BoNT-A is the reduction of facial wrinkles, formally approved by the FDA in 2000.…”

Section: Clinical Uses In Human Medicinementioning

confidence: 95%

“…The retrograde transport of catalytically active BoNT-A was found in projection neurons in cellular and animal models (Matak and Lacković, 2014). Animal data from rodents suggest the axonal transport and transcytosis in facial and spinal motor neurons, which may account for observed distant effects (Matak et al, 2016;Caleo et al, 2018;Matak, 2020). The fact that BoNT-A may undergo transcytosis and reach second order synapses suggests a process of transport very similar to tetanus neurotoxin (TeNT).…”

Section: Mechanism Of Action Of Botulinum Neurotoxinmentioning

confidence: 99%

Botulinum toxin: From the natural cause of botulism to an emerging therapeutic in veterinary medicine

2022

Veterinaria

View full text Add to dashboard Cite

show abstract

Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats

Cited by 21 publications

References 45 publications

Mechanisms of Botulinum Toxin Type A Action on Pain

Mechanisms of Botulinum Toxin Type A Action on Pain

Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy

Botulinum toxin: From the natural cause of botulism to an emerging therapeutic in veterinary medicine

Contact Info

Product

Resources

About